Institut du cancer de Montréal

What Institut du cancer de Montréal does

Institut du cancer de Montréal (ICM) is a privately registered organization headquartered in Montréal, Canada, founded in 1974 and operating with a headcount of 101-250 employees. Its stated tagline — "La recherche d'aujourd'hui, c'est le traitement de demain" (Today's research is tomorrow's treatment) — signals a translational research mission oriented toward converting laboratory findings into clinical cancer treatments. The input classifies the entity as for-profit, though the organization name, founding era, and research mission are more consistent with a non-profit or hospital-affiliated research institute model; this classification discrepancy is noted as a data-quality issue. No products, services, customer segments, partnerships, pricing, or distribution channels are disclosed in the supplied input, and the corporate website (icm.qc.ca) returned only a verification/loading page during data collection, preventing any first-party confirmation of current operations, research programs, or commercial offerings.

The underlying business model, revenue mechanics, and go-to-market strategy cannot be characterized from the available data. No management team, board, ownership structure, subsidiaries, funding rounds, or investor information has been disclosed. There are no records of mergers, acquisitions, leadership changes, regulatory actions, certifications, patents, trademarks, or strategic alliances in the input. As a result, the investment-relevant dimensions of the company — commercial model, capital structure, and operating cadence — remain opaque.

Given the data thinness, the most defensible interpretation is that ICM operates as a cancer research entity, likely funded through a combination of public research grants, institutional support, private philanthropy, and possibly contract research arrangements, though none of these revenue channels is confirmed by source. Until richer primary-source data becomes available, any commercial or financial assessment should be treated as provisional. The source ID supporting the available firmographic data is, with extensive data gaps across product, customer, and financial dimensions.

Name

Institut du cancer de Montréal

Website

https://icm.qc.ca

Company type

Private

Founded year

1974

Headcount range

101–250 employees

Short description

Institut du cancer de Montréal is a private Montréal-based cancer research organization founded in 1974, employing 101-250 staff, with a stated mission of translational oncology research that bridges today's laboratory findings with tomorrow's clinical cancer treatments.

Ownership category

akta.pro rank

Product category

Cancer Research and Treatment Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Cancer research
• Oncology research
• Cancer treatment
• Clinical research
• Medical research

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Core offering

Institut du cancer de Montréal is a Montreal-based cancer research and treatment organization founded in 1974. Per its tagline ("La recherche d'aujourd'hui, c'est le traitement de demain"), it focuses on cancer research intended to translate into future cancer treatments for patients. The organization employs 101–250 staff and operates from Montréal, Canada, delivering cancer-focused research and care services locally.

Product overview

No product information available. The source content consists of a verification/loading page that does not contain any details about the organization's products, services, or offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer research and treatment services Cancer research and treatment services delivered by a Montréal-based organization to cancer patients, focused on translating research into clinical treatment, per the organization's tagline.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Fred Hutchinson Cancer Center: US NCI-designated cancer research center with a strong translational and clinical-trials focus. Comparable as a non-university specialty cancer research organization of similar mission scope.
• Dana-Farber Cancer Institute: Major US-based cancer research and treatment institute affiliated with Harvard. Comparable as a globally recognized, single-disease research institution with a translational bench-to-bedside model.
• CHUM (Centre hospitalier de l'Université de Montréal): The university hospital center in Montreal with which ICM is closely affiliated. Comparable as the broader acute-care institution that houses cancer clinical activity and shares research infrastructure.

Regional players

• Institut national du cancer (France): French national cancer agency coordinating cancer research, care, and public-health initiatives. Comparable as a French-speaking, cancer-specific research and policy organization with similar vertical focus.
• European Institute of Oncology: Italy-based cancer research and treatment institute with a translational research mandate. Comparable as a European specialty cancer institute with a similar bench-to-bedside model.

Direct peers

• BC Cancer: Provincial cancer care and research agency serving British Columbia. Directly comparable as a Canadian cancer-focused research and treatment organization with similar translational research scope.
• Institut de recherches cliniques de Montréal (IRCM): Montreal-based biomedical research institute with a similar profile of 100+ researchers, university affiliation, and translational research mandate. Directly comparable as a sister research institute in the same city and ecosystem.
• Princess Margaret Cancer Centre: Canada's largest cancer research and treatment hospital, affiliated with the University of Toronto. Directly comparable as a Canadian, university-affiliated cancer research and clinical care institution of similar vertical focus.
• Ottawa Hospital Research Institute: Large Canadian hospital-affiliated research institute with significant cancer research programs. Comparable as a mid-sized Canadian academic research organization with translational mandate.
• Lady Davis Institute (Jewish General Hospital): Montreal-based hospital-affiliated research institute with significant cancer and clinical-research programs. Comparable as a peer Montreal research institute with overlapping translational mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut du cancer de Montréal